References
- Dipiro, J. T., Talbert, R. L., Yee, G. C., Matzke, G. R., Wells, B. G. and Posey, L. M. : Pharmacotherapy, 7th edition: A Pathophysiologic Approach, McGraw-Hill Companies (2008).
- 질병관리본부 : 결핵퇴치 2030 Revision - Elimination of TB 2030, 질병관리본부 (2008).
- 질병관리본부 전염병관리과 : 질병관리백서 2009, 질병관리본부 (2009).
- Koda-Kimble, M. A., Young, L. Y., Kradjan, W. A., Guglielmo, B. J., Alldredge, B. K. and Corelli, R. L. : Applied Therapeutics, 8th edition, Lippincott Williams & Wilkins (2005).
- Centers for disease Control (CDC), American Thoracic Society, and Infectious Diseases Society of America : Treatment of Tuberculosis, MMWR, 52(RR11), 1-77. http://www.cdc.gov/ mmwr/PDF/rr/rr5211.pdf (2003).
- American Thoracic Society : An official ATS statement: hepatotoxicity of antituberculosis therapy. Am. J. Respir. Crit. Care. Med. 174, 935 (2006). https://doi.org/10.1164/rccm.200510-1666ST
- Tostmann, A., Boeree, M. J., Aarnoutse, R. E., de Lange, W. C., van der Ven, A. J. and Dekhuijzen, R. : Antituberculosis Druginduced Hepatotoxicity : Concise up-to-date review. Journal of Gastroenterology and Hepatology 2008, 192 (2006).
- Sarma, G. R., Immanuel, C., Kailasam, S., Narayana, A. S. and Venkatesan, P. : Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin. Am. Rev. Respir. Dis. 133, 1072 (1986).
- Steele, M. A., Burk, R. F. and Desprez, R. M. : Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest. 99, 465 (1991). https://doi.org/10.1378/chest.99.2.465
- Thompson, N. P., Caplin, M. E., Hamilton, M. I., Gillespie, S. H., Clarke, S. W., Burroughs, A. K. and Mclntyre, N. : Anti-tuberculosis medication and the liver : dangers and recommendations in management. Eur. Respir. J. 8, 1384 (1995). https://doi.org/10.1183/09031936.95.08081384
- Kishore, P. V., Palaian, S., Paudel, R., Mishra, P., Prabhu, M. and Shankar, P. R. : Drug induced hepatitis with anti-tubercular chemotherapy : Challenges and difficulties in treatment, Kathmandu University. Medical Journal 5, 256 (2007).
- Teleman, M. D., Chee, C. B., Earnest, A. and Wang, Y. T. : Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Shingapore. Int. J. Tuberc. Lung. Dis. 6, 699 (2002).
- Singla, R., Sharma, S. K., Mohan, A., Makharia, G., Sreenivas, V., Jha, B., Kumar, S., Sarda, P. and Singh, S. : Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J. Med. Res. 132, 81 (2010).
- Pande, J. N., Singh, S. P. N., Khilnani, G. C., Khilnani, S. and Tandon, R. K. : Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 51, 132 (1996). https://doi.org/10.1136/thx.51.2.132
- Marzuki, O. A., Fauzi, A. R. M., Ayoub, S. and Kamarul Imran M. : Prevalence and risk factors of anti-tuberculosis druginduced druginduced hepatitis in malaysia. Singapore Med. J. 49, 688 (2008).
- El Gharbi, L., Baccar, M. A., Azzabi, S., Aouina, H., Kallel, H., Daghfous, R. and Bouacha, H. : Risk factors of side effects of antituberculosis drugs. Tunis. Med., 84 487 (2006).
- 정의준, 남수연, 박란영, 이지현, 이창수, 이계희 : 항결핵제 복용 중 발생한 약인성 간손상의 임상상. 대한소화기학회지 40, 112 (2002).
- 손경선, 김남재, 서지원, 정연채, 김주옥, 김선영 : 항결핵 삼제요 법(HRE) 중 혈청 AST/ALT의 상승과 B형 간염의 혈청학적 지표와의 관계. 결핵 및 호흡기질환 37, 288 (1990).
- 장성욱 : 항결핵 약제에 의한 유해반응에 관한 연구, 단국대학교 대학원 석사학위논문 (2007).
- 윤용범, 정영화, 이영상 : 항결핵약제에 의한 간독성에 대한 임상적 연구. 대한소화기학회지 21, 326 (1989).
- 이혜연, 홍경란, 신미정, 손현경, 진현정, 홍경자, 나현오 : 항결 핵제의 부작용 발현실태조사. 병원약사회지 6, 398 (1999).
- Khalid, M., Akhtar, H., Krishan, L. J., Abu, T., Badar-uddin, A. and Salkeen, S. : Hepatotoxicity with Antituberculosis Drugs: The risk factors. Pak. J. Med. Sci. January 23, 33 (2007).
- Khalili, H., Dashti-Khavidaki, S., Rasoolinejad, M., Rezaie, L. and Etminani, M. : Anti-tuberculosis drugs related hepatotoxicity; incidence, risk factors, pattern of changes in liver enzymes and outcome. DARU 17, 163 (2009).
- Shargel, M., Alan, H. M., Paul, F. S. and Larry, N. S. Comprehensive Pharmacy Review, sixth edition, Philadelphia, Lippincort Williams & Wilkins (2007).
- 대한결핵 및 호흡기학회 결핵 진료 지침 위원회 : 결핵의 진료 지침. 대한결핵 및 호흡기학회 (2005).
- Baniasadi, S., Eftekhari, P., Tabarsi, P., Fahimi, F., Raoufy, M. R., Masjedi, M. R. and Velayati, A. A. : Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. Eur. J. Gastroenterol. Hepatol. 22, 1235 (2010). https://doi.org/10.1097/MEG.0b013e32833aa11b
- Eminzade, S., Uras, F. and Izzettinl, F. V. : Silymarin protects liver against toxic effects of anti-tuberculosis drugs in experimental animals. Nutrition & Metabolism 5 (2008).
- Lee, M. : Basic skills in Interpreting Laboratory Data, 4th edition, American Society of Health-System Pharmacists (2009).
- Krishnaswamy, K., Prasad, C. E. and Murthy. K. J. : Hepatic dysfunction in undernourished patients receiving isoniazid and rifampicin. Trop. Geogr. Med. 43, 156 (1991).
- 신수린, 김창환, 김성은, 박용범, 이재영, 모은경, 김철홍, 엄광석, 장승훈, 김동규, 이명구, 정기석 : 결핵으로 입원한 환자의 병원내 사망과 관련된 인자. Tuberic. Respir. Dis. 61, 233 (2006). https://doi.org/10.4046/trd.2006.61.3.233